Real-world management of ovarian cancer in women living with HIV: treatment exposure, immune monitoring, and care barriers in a five-case series.

Authors

Yang Zhang, Fuxiang Wang, Mingchuan Guo, Jianyu Wan, Huiyan Liao, Ting Mao, Lu Cui, Wenming Cao, Yutao Gao

Published in

Frontiers in oncology. Volume 16. Pages 1942370. Epub Sep 30, 2026.

Abstract

With improved survival among people living with HIV (PLWH), non-AIDS-defining cancers have become increasingly prominent. Women living with HIV (WLWH) remain underrepresented in ovarian cancer trials, leaving limited evidence on the tolerability of standard therapies, including chemotherapy, anti-VEGF agents, and PARP inhibitors. These patients also face unique care barriers beyond biological uncertainties.
This retrospective review included five WLWH diagnosed with ovarian cancer (June 2022-March 2024). Three received anticancer treatment; one refused chemotherapy and was lost to follow-up; one had biopsy only. We collected data on demographics, HIV history, tumor characteristics, treatment exposure, adverse events (CTCAE v5.0), CD4⁺/CD8⁺ counts, and HIV RNA, focusing safety and immune analyses on the three treated patients.
Median age was 51 years; four had stage III-IV disease. No treatment-related deaths, persistent HIV rebound, or AIDS-defining events occurred. During first-line paclitaxel/carboplatin, one patient developed grade 3 neutropenia managed with G-CSF, but later developed significant thrombocytopenia on niraparib requiring dose reduction and hospitalization. Among two patients receiving bevacizumab, CD4⁺ patterns diverged: one showed a transient decline (387 to 259 cells/μL) with concurrent nedaplatin; another maintained stable counts (150 to 200 cells/μL). One patient had transient, self-limited HIV RNA elevation concurrent with disease progression, which resolved spontaneously.
This series provides real-world observations that platinum-based and targeted therapies may be delivered to selected WLWH with close monitoring. The heterogeneous CD4⁺ responses highlight the need for individualized immune surveillance rather than attributing changes to any single agent. Integrated oncologic-HIV care and attention to socioeconomic barriers remain critical for this underrepresented population.

PMID:
42876492
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.